Dr. King was with TaiGen Biotechnology Co. Ltd (“TaiGen”), a Taiwan company in the biotechnology business, from June of 2005 to July 2017. There he served in various positions including Senior Vice President of Research and Development. TaiGen is engaged in the development of therapeutics for infectious diseases, cancer and diabetes-related complications. TaiGen developed Taigexyn®(Nemonoxacin), a novel antibiotic which was one of the first NCEs developed by a Taiwanese company to receive market approval.

Prior to that, Dr. King was a Director at Albany Molecular Research Inc. (“AMRI”), a New York corporation, from January 2003 to June 2005, the Assistant Director at Medicinal Chemistry Department of AMRI from January 2000 to December 2002, and the Assistant Director at Chemical Development Department of AMRI from August 1997 to January 2000.

Dr. King received his Ph. D. degree of organic chemistry from University of Utah in March 1980, and B.S. degree of chemistry from National Taiwan Normal University in July 1972.